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Abstract
Background: The late endosomal LAMTOR complex serves as a convergence point for both the RAF/MEK/ERK and the PI3K/
AKT/mTOR pathways. Interestingly, both of these signalling cascades play a significant role in the aetiology of breast cancer.
Our aim was to address the possible role of genetic polymorphisms in LAMTOR2 and LAMTOR3 as genetic risk factors for
breast cancer.
Methodology/Results: We sequenced the exons and exon–intron boundaries of LAMTOR2 (p14) and LAMTOR3 (MP1) in 50
prospectively collected pairs of cancerous tissue and blood samples from breast cancer patients and compared their genetic
variability. We found one single nucleotide polymorphism (SNP) in LAMTOR2 (rs7541) and two SNPs in LAMTOR3 (rs2298735
and rs148972953) in both tumour and blood samples, but no somatic mutations in cancerous tissues. In addition, we
genotyped all three SNPs in 296 samples from the Risk Prediction of Breast Cancer Metastasis Study and found evidence of a
genetic association between rs148972953 and oestrogen (ER) and progesterone receptor negative status (PR) (ER: OR = 3.60
(1.15–11.28); PR: OR = 4.27 (1.43–12.72)). However, when we additionally genotyped rs148972953 in the MARIE study
including 2,715 breast cancer cases and 5,216 controls, we observed neither a difference in genotype frequencies between
patients and controls nor was the SNP associated with ER or PR. Finally, all three SNPs were equally frequent in breast cancer
samples and female participants (n = 640) of the population-based SAPHIR Study.
Conclusions: The identified polymorphisms in LAMTOR2 and LAMTOR3 do not seem to play a relevant role in breast cancer.
Our work does not exclude a role of other not yet identified SNPs or that the here annotated polymorphism may in fact play
a relevant role in other diseases. Our results underscore the importance of replication in association studies.
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Introduction
Scaffold proteins were originally identified in yeast and are now
recognized to contribute to the specificity of MEK/ERK pathways
in mammalian cells. LAMTOR3 (MP1) was identified in a yeast
two-hybrid screen as a specific binding partner of MEK1 [1], that
is recruited to late endosomes by the adaptor protein LAMTOR2
(p14) [2]. MP1 and p14 are structurally almost identical and form
a very stable heterodimeric complex that is required for ERK
activation on endosomes [3,4]. Using conditional gene disruption
of p14, it was previously shown that the p14/MP1-MEK1
signalling complex regulates late endosomal traffic, EGFR
degradation and cellular proliferation [5]. This function is essential
for early embryogenesis and during tissue homeostasis as revealed
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by epidermis-specific deletion of p14 [5]. Taken together,
endosomal p14/MP1-MEK1 signalling has a specific and essential
function in vivo: it contributes to the regulation of late endosomal
traffic by extra-cellular signals, that in turn is required to maintain
tissue homeostasis.
Anchorage of the p14/MP1/MAP kinase pathway to late
endosomes is mediated by a small lipid raft adaptor called
LAMTOR1 (p18), which directly binds endosomal lipids [6]. The
trimeric complex p18/p14/MP1 was recently shown to mediate
the translocation of mTORC1 to lysosomal membranes, a critical
event in amino acid signalling to mTORC1 [7]. The mTORC1
kinase promotes growth in response to growth factors, energy
levels, and amino acids, and its activity is often deregulated in
disease conditions. In brief, these data highlight the role of the
endosomal scaffold complex p18/p14/Mp1 as a convergence
point of signalling pathways controlling proliferation (Figure 1).
Progression, proliferation, and hormone independent growth of
breast cancer cells is dependent on MAP kinase (ERK) activity [8].
Furthermore, there are consistent reports that primary breast
tumors and tissues display elevated expression and activity levels of
ERK [9]. In most breast cancers, ERK hyper-activation is due to
over-expression and/or constitutive activation of upstream regu-
lators like ErbB2, c-Src or GrB2 [10,11,12]. Sustained ERK1/2
signalling in cooperation with transforming growth factor ß
(TGFß) activation promote epithelial mesenchymal transition
(EMT) and increase invasiveness and metastatic potential of
cultured mammary epithelial cells [13]. In brief, ERK activation
induces matrix metalloproteinases that degrade collagen, it can
inactivate integrin-meditated cell adhesion and activates the
myosin light chain thereby eliciting cell migration. Importantly,
the Ets-1 transcription factors are key ERK substrates that have
been shown to induce EMT and invasiveness in a number of
breast cancer cell lines [14,15]. Several anti-cancer therapies result
in the induction of the Raf/MEK/ERK pathway that may
provide a survival signal for the tumour, thereby potentiating
resistance to treatment. For example, ERK1/2 phosphorylates
Ser118 of oestrogen receptor alpha, providing a mechanism by
which the oestrogen receptor can be activated in a ligand
independent manner [16].
The PI3K/AKT signalling cascade is another major player in
cancer progression. Mutations in the PI3K subunit p110 are found
in roughly 25% of breast cancers [17,18]. Furthermore, loss of the
tumour suppressor protein PTEN has been directly implicated in
hereditary breast cancer [19]. Both the RAF/MEK/ERK and the
PI3K/AKT pathways modulate several key apoptotic players
thereby transducing a survival signal. The ERK pathway regulates
BcL-2, Bad, Mcl-1, Bim, Survivin and Caspase 9 [20,21,22]. The
PI3K/AKT pathway phosphorylates Bim, Bad, XIAP and p21
[23,24,25].
It has been recently shown that treatment of breast cancer cells
with MEK or mTOR inhibitors and either Doxorubicin or
Tamoxifen results in a synergistic response that highlights the
advantages of combining classical chemotherapy with targeted
adjuvant treatments [19]. For example, Tamoxifen resistant breast
cancer cells with overexpressed/activated v-akt murine thymoma
viral oncogene homolog (AKT) or lack of phosphatase and tensin
homologue (PTEN) may benefit from Rapamycin treatment, a
highly specific mTOR inhibitor. In addition, the complementary
use of RAF/MEK/ERK inhibitors may provide an added value in
the treatment of this type of tumours since ERK is known to
phosphorylate TSC2. The TSC1/TSC2 complex, also known as
the tuberous sclerosis complex, controls the small G-protein Rheb
through its GAP activity, thereby functioning as a critical negative
regulator of mTORC1.
Interestingly, in 2007, Conrad et al. submitted a patent on
LAMTOR3 (Mp1) as a diagnostic and therapeutic target for breast
cancer treatment and prevention (United States patent Applica-
tion No. US 2007/0172843 A1; International publication nr.
W=2007/033118 A2). In addition, a recent publication from the
same group reports that LAMTOR3 (Mp1) is required for the
survival of estrogen receptor positive breast cancer cell lines [26].
Taking into consideration the above report and recent findings
identifying the LAMTOR complex as a convergence point for
both the ERK and mTORC1 pathways, we aimed to investigate
the potential role of mutations in LAMTOR3 and LAMTOR2 in the
aetiology of breast cancer.
Materials and Methods
Ethics Statement
This study was approved by the ethics committee of the
Innsbruck Medical University (study code UN3377).
Patient Characteristics at the Screening Stage
For mutation screening, tissue samples of 50 consecutive breast
cancer patients were prospectively collected at the Innsbruck
Medical University starting in July 2009. Patients aged 18 or older,
who had signed an informed consent, were consecutively included
in the study. The following clinical parameters were collected: age;
menopausal status; tumour histology; tumour size; tumour grade;
lymph node status; oestrogen receptor status; progesterone
receptor status; HER2 (human epidermal growth factor receptor
2) status; and presence of metastasis.
Sequencing of Exons in LAMTOR2 (p14) and LAMTOR3
(MP1)
Genomic DNA was extracted from frozen tumour tissue or from
peripheral blood collected on EDTA on a BioRobot EZ1
advanced Workstation with the EZ1 DNA tissue or blood kit
(QIAGEN, Hilden, Germany) and quantified with a NanoDrop
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA).
Amplification and sequencing primes were designed with Visual
OMP (DNA Software, Inc., Ann Arbor, MI).
All four exons of the LAMTOR2 gene (following the nomencla-
ture of transcript ENST00000368305, Ensembl Release 52; www.
ensembl.org) were amplified in 2 PCR reactions and sequenced
with 8 primers (Table S1). An overview of the amplification and
sequencing strategy of the exons within LAMTOR2 is given in
Figure S1.
Five out of seven exons of the LAMTOR3 gene (following the
nomenclature of transcript ENST00000226522, Ensembl Release
52; www.ensembl.org) were amplified in 4 PCR reactions and
sequenced with 14 primers (Table S2). The genomic region
including Exon 1 and Exon 2 could be amplified in one PCR
reaction. Exon 3, Exon 4, Exon 5 and Exon 6 were each very short
and had long intronic stretches between each other, so that none
of these exons could be targeted with another PCR reaction. Exon
3 codes for the first alpha helix of LAMTOR3, is only 35bp long,
lacks putative protein binding sites and shows low amino acid
conservation [4]; therefore, it was not of particular structural
interest and was excluded from sequencing. Exon 6 codes for two
of the central b-strands of LAMTOR3. Non-synonymous
mutations in Exon 6 (64bp) are assumed to have two possible
consequences: if the properties of the amino acids were
maintained, LAMTOR3 would fold correctly and the protein
would be as functional as the wild type. If the amino acid
properties significantly changed, the correct assembly of the
central b-sheet would be impaired, thereby completely abolishing
LAMTOR2/LAMTOR3 Polymorphisms and Breast Cancer
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LAMTOR3 function, with the consequence that LAMTOR3
molecules would be degraded by quality control mechanisms. If
such mutations existed, they would lead to embryonic lethality as
was observed in LAMTOR2 knockout mice [5]. Therefore, we
also excluded Exon 6 from sequencing. An overview of the
amplification and sequencing strategy of the selected exons within
LAMTOR3 is given in Figure S2.
All fragments except for MP1-1 were amplified in a total
reaction volume of 25 ml, containing 70–130 ng of DNA, 0.5 ml of
Herculase II Fusion DNA Polymerase (Stratagene, La Jolla, USA),
5 ml of PCR reaction buffer, 250 mM each dNTP, and 0.25 mM
each primer. The reaction cocktails were heated to 95uC (2 min)
and then put through 35 amplification cycles: 95uC for 20 s, 55uC
for 20 s, and 72uC for 60 sec and a final extension phase at 72uC
for 10 min. Fragment MP1-1 was amplified in a total reaction
volume of 25 ml, containing 60 ng of DNA, 0.5 ml of KAPA HiFi
HotStart DNA Polymerase (KAPA Biosystems, Boston, USA), 5 ml
of 5X KAPA HiFi GC Buffer, 0.5 ml KAPA dNTP Mix (10 mM
each dNTP), and 0.3 mM each primer. The reaction cocktails were
heated to 95uC (5 min) and then put through 30 amplification
cycles: 98uC for 20 s, 56.7uC for 15 s, and 72uC for 45 sec and a
final extension phase at 72uC for 5 min.
PCR products were purified using QIAvac vacuum manifolds
(QIAGEN) and eluted in 50ml distilled water according to the
manufacturer’s protocol. For cycle sequencing, 3 ml of purified
PCR product were combined with the sequencing master mix
(containing 2 ml BigDye Terminator v1.1 Cycle Sequencing RR
mix [AB], 2 ml Sequencing Buffer [AB], 0.3 mM primer, and
distilled water up to 10 ml) and cycled (after a first denaturation
step of 96uC, 2 min) for 30 cycles of 30 s at 96uC, 20 s at 55uC,
and 1 min at 60uC. Purification of cycle-sequencing products with
Sephadex (GE Healthcare) was performed according to the
procedure described in Brandsta¨tter et al. [27].
Electrophoretic separation was carried out on an ABI3130xl
capillary sequencer with POP-7 and a 36 cm capillary array.
Risk Prediction of Breast Cancer Metastasis Study
For studying the effects of the identified variants in a breast
cancer sample, one single nucleotide polymorphism (SNP) in
LAMTOR2 (rs7541) and two SNPs in LAMTOR3 (rs2298735 and
rs148972953) were genotyped using a TaqManH SNP Genotyping
Assay on a 7900HT Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA) in 296 samples of the Risk Prediction
of Breast Cancer Metastasis Study. This study is a multicenter
study including prospectively collected breast cancer samples from
the cities Innsbruck (Austria), Salzburg (Austria) and Meran (Italy).
Patients aged 18 or older, who had signed an informed consent,
were consecutively included in the study. Detailed information on
tumour characteristics (e.g., hormone receptor status) and
treatment (e.g. chemotherapy, endocrine therapy, and radiother-
apy) were collected using clinical and pathological records. The
Risk Prediction of Breast Cancer Metastasis Study was approved
by the ethics committee of the Innsbruck Medical University
(study code AM330a). The genotyping success rates were 97.3%
for rs7541, 99.3% for rs2298735, and 97.3% for rs148972953.
Replication: MARIE Study
For a more detailed analysis, the SNP rs148972953 was
genotyped using a TaqManH SNP Genotyping Assay on a
7900HT Fast Real-Time PCR System (Applied Biosystems, Foster
City, CA) in 7,931 samples of the MARIE Study. The MARIE
(Mammary carcinoma Risk factor Investigation) study population
comprises breast cancer patients who participated in a population-
based case-control study conducted in two German study regions
(Hamburg and Rhine-Neckar-Karlsruhe) [28]. The study was
approved by the ethics committees of the University of Heidelberg
and the University of Hamburg. Patients were eligible if they had a
histologically confirmed primary invasive (stage I-IV) or in situ
breast tumour, were 50 to 74 years old, resident in the study
region, and German-speaking. Of the 6,114 eligible patients, 3,919
(64.1%) participated in the study. Detailed information on tumour
characteristics (e.g., hormone receptor status) and treatment (e.g.
chemotherapy, endocrine therapy, and radiotherapy) were
collected using clinical and pathological records/attending physi-
cians. Two controls per case were randomly selected from
population registries frequency-matched by year of birth and
study region. Of the 17,093 eligible controls, 7,421 (43.3%)
participated in the study. For the present analyses, 2,767 cases and
5,324 controls were included, excluding subjects without blood
samples and genotype information. Information on socio-econom-
ic and lifestyle factors was collected at baseline by means of a
personal interview. An overview of all three breast cancer
populations is given in Table 1. The genotyping success rates
were 98.1% for cases, and 98.0% for controls. The fraction of
samples that were genotyped twice for quality assurance were
9.5%, the genotyping discordance rate was 0%. Therefore
genotype information was available for 2,715 cases and 5,216
controls.
Figure 1. The LAMTOR complex as a convergence point of
MAPK and mTORC1 pathways (Schematic overview). Internal-
ized activated receptors keep their ability to signal while they traffic
through the endocitic compartment. The arrival at late endosomes/
multivesicular bodies of the activated receptor and the detection of
aminoacids in the lumen of the organelle, trigger a cascade of
phosphorylation events leading to the local activation of both mTORC1
and ERK1/2. The p18/Mp1/p14 complex, also known as the LAMTOR
complex was shown to function as a convergence point for both
pathways. Both signaling cascades were simplified for didactic reasons.
doi:10.1371/journal.pone.0053768.g001
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SNP Frequencies in a Healthy Working Population:
SAPHIR Study
For studying the frequency of the identified variants in a healthy
working population, one SNP in LAMTOR2 (rs7541) and two
SNPs in LAMTOR3 (rs2298735 and rs148972953) were genotyped
using a TaqManH SNP Genotyping Assay on a 7900HT Fast
Real-Time PCR System (Applied Biosystems, Foster City, CA) in
female participants of the SAPHIR Study. The Salzburg
Atherosclerosis Prevention Program in Subjects at High Individual
Risk (SAPHIR) is an observational study conducted in the years
1999–2002 involving 1,770 healthy unrelated subjects: 663
females from 39 to 67 years of age and 1,107 males from 39 to
66 years of age [29]. Study participants were recruited by health
screening programs in large companies in and around the city of
Salzburg. DNA was available for 640 female samples. The fraction
of samples that were genotyped twice for quality assurance were
4%, the genotyping discordance rate was 0%. The genotyping
success rates were 99.1% for rs7541, 97.3% for rs2298735, and
97.2% for rs148972953.
Statistical and Bioinformatic Analysis
The genotype distribution was used to calculate minor allele
frequencies and deviations from Hardy-Weinberg equilibrium
were evaluated using a Chi-square test. Due to the low minor allele
frequency of rs148972953, heterozygous and homozygous minor
allele carriers were assessed combined in comparison to major
allele carriers. Differences in allele frequencies between carriers
and non-carriers of rs148972953 by oestrogen receptor status,
progesterone receptor status, metastasis at baseline and metastasis
after treatment were calculated by using a Chi-squared test. Odds
ratios with a 95% confidence interval were calculated for
estimating the relationship between rs148972953 and oestrogen
receptor status (ER), progesterone receptor status (PR) and
metastasis [30]. Statistical analyses were performed with SPSS
(version 19), R (version 2.15.0) and SAS (version 9.2).
Following functional considerations based on the SNP position,
the potential effects of the three SNPs were investigated using
selected bioinformatic applications [31]. Especially, the SNPs were
checked for exonic splicing regulators (ESRs) with F-SNP [32] and
miRNA binding sites with Patrocles [33] and mirRBase [34].
Results
Search for Genetic Variability in LAMTOR2 and LAMTOR3
Sequencing of the exons and exon-intron boundaries of both
LAMTOR2 and LAMTOR3 revealed three SNPs to occur in a
sequencing sample of 50 breast cancer patients, but no novel
mutations. One SNP was found in LAMTOR2 (rs7541) and two
SNPs within LAMTOR3 (rs2298735 and rs148972953) (Table 2).
Our hypothesis that LAMTOR2 and LAMTOR3 gene regions
would harbour somatic mutations in tumour tissue was not
confirmed; all SNPs that were found were present in both benign
(DNA derived from whole blood) and cancerous tissue.
Bioinformatic Analysis
Bioinformatic analysis indicated that the synonymous SNP
rs7541 in exon 2 of LAMTOR2 could possibly affect splicing
regulation (predicted by both F-SNP [32] and PupaSuite [35]) by
deletion of a splicing silencer element. However, none of the
annotated NCBI transcripts actually shows splicing in this region.
The SNP rs2298735, which is located in the 59UTR of
LAMTOR3, had a very low functional score in F-SNP, and we
also did not find transcription factor binding sites (as predicted
with FASTSNP [36]).
Interestingly however, the rare allele of SNP rs148972953 in the
39UTR of LAMTOR3 abolishes a putative binding site for the
miRNA mir-126* (‘‘TAATAATA’’) (as analyzed with Patrocles
[33] and miRBase [34]). mir-126* and its complement mir-126,
which are encoded by intron 7 of the egfl7 gene, have been
reported to impair cancer progression through signalling pathways
that control tumour cell proliferation, migration, invasion, and
survival in a wide variety of cancers [37,38,39,40,41,42,43],
especially in breast cancer [44,45].
Genetic Association Studies and Comparison with
Healthy Controls
As our sequencing sample was relatively small (n = 50), and as
the SNP rs148972953 in LAMTOR3 had a minor allele frequency
(MAF) of 4%, we investigated whether a healthy working
population sample would show different genotype distributions
than the breast cancer sample. Therefore, we genotyped all three
SNPs in female participants of the SAPHIR population (n= 640).
The allele and genotype frequencies in SAPHIR women were
similar to those in our sequencing sample (p.0.05; Table 2).
For the analysis of genetic association, we combined the samples
for sequencing and those in the Risk Prediction of Breast Cancer
Metastasis Study since they were collected at the same University
Clinic in the same manner. In the combined breast cancer sample,
Table 1. Characteristics of the breast cancer studies.
Sequencing RPBCMS MARIE cases
n 50 296 2,715
Age at diagnosis (years) 58.3613.4 59.7613.3 62.466.1
Percentage of premenopausal
women
31.3% 34.3% 9.2%
Histology
IDC 74.0% 75.0% 66.3%
ILC 16.0% 15.5% 19.9%
DCIS 1.7% 6.3%
other 10.0% 7.8% 7.3%
Tumour size
with the diameter less
than 2 cm
54.0% 58.0% 51.5%
with the diameter more
than 2 cm
46.0% 42.0% 42.2%
Tumour grade
I 4.0% 8.0% 17.4%
II 78.0% 69.5% 48.1%
III 18.0% 22.5% 28.1%
Oestrogen receptor status
positive 84.0% 86.3% 79.0%
negative 16.0% 13.7% 21.0%
Progesterone receptor status
positive 76.0% 75.2% 67.0%
negative 24.0% 24.8% 33.0%
Notes: the age at diagnosis is indicated as mean value 6 standard deviation.
Abbreviations:
IDC… infiltrative ductal carcinoma.
ILC… infiltrative lobular carcinoma.
DCIS… ductal carcinoma in situ.
RPBCMS… Risk Prediction of Breast Cancer Metastasis Study.
doi:10.1371/journal.pone.0053768.t001
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Table 2. Genotype frequencies of the analyzed SNPs by study population.
LAMTOR2 LAMTOR3
rs7541 rs2298735 rs148972953
Chromosome: Base pair position 1:156,025,096 4:100,815,617 4:100,802,946
Located in: Exon 2 59UTR 39UTR
Ancestral/derived allele C/T T/G A/G
SNP effect Synonym – –
GD: AA/Aa/aa: Sequencing 66.0/28.0/6.0% 28.0/40.0/32.0% 92.0/8.0/0.0%
GD: AA/Aa/aa: RPBCMS 75.4/22.2/2.4% 39.1/45.2/15.7% 96.5/3.5/0.0%
GD: AA/Aa/aa: SAPHIR women 70.3/27.0/2.7% 39.5/44.5/16.0% 96.0/3.9/0.1%
GD: AA/Aa/aa: MARIE cases n.a. n.a. 97.1/2.9/0.0%
GD: AA/Aa/aa: MARIE controls n.a. n.a. 97.3/2.7/0.0%
MAF: Sequencing (n = 50) 20.0% 52.0% 4.0%
MAF: RPBCMS (n = 296) 13.5% 38.3% 1.7%
MAF: SAPHIR women (n = 640) 16.2% 38.2% 2.1%
MAF: MARIE cases (n = 2,715) n.a. n.a. 1.5%
MAF: MARIE controls (n = 5,216) n.a. n.a. 1.4%
HWE p-value: Sequencing 0.376 0.159 0.768
HWE p-value: RPBCMS 0.387 0.466 0.764
HWE p-value: SAPHIR women 0.900 0.140 0.153
HWE p-value: MARIE cases n.a. n.a. 0.435
HWE p-value: MARIE controls n.a. n.a. 0.316
Notes:
Call rates in all study populations were above 98%.
MAF… Minor allele frequency.
HWE… p-value for test for Hardy-Weinberg-Equilibrium (Chi-Square test).
GD… Genotype distribution (in %).
RPBCMS… Risk Prediction of Breast Cancer Metastasis Study.
doi:10.1371/journal.pone.0053768.t002
Table 3. Genetic association of rs148972953 with tumour characteristics (oestrogen and progesterone receptor status and
metastases).
Oestrogen receptor Progesterone receptor
Study population rs148972953 positive negative positive negative
Sequencing + Wild-type (GG) 266 41 234 73
RPBCMS Carrier (AG or AA) 9 5 6 8
Combined p-value 0.035 0.006
(n = 321) OR (95% CI) 1 3.60 (1.15–11.28) 1 4.27 (1.43–12.72)
MARIE cases Wild-type (GG) 1919 504 1610 809
(n = 2,499) Carrier (AG or AA) 58 18 51 25
p-value 0.543 0.920
OR (95% CI) 1.18 (0.69–2.02) 1 0.97 (0.60–1.58)
Notes:
Due to the low minor allele frequency of rs148972953, heterozygous and homozygous mutation allele carriers were assessed combined in comparison to wild-type
allele carriers assuming a dominant mode of inheritance.
For this analysis, only samples with complete information on ER, PR and an rs148972953 genotype were taken into consideration.
OR … odds ratio.
95% CI … 95% confidence interval.
RPBCMS… Risk Prediction of Breast Cancer Metastasis Study.
doi:10.1371/journal.pone.0053768.t003
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rs148972953 in LAMTOR3 was found to be strongly associated
with negative progesterone receptor status (OR=4.27 (1.43–
12.72); Table 3) and with negative oestrogen receptor status of the
tumour (OR=3.60 (1.15–11.28); Table 3).
Replication in the MARIE Study
Encouraged by the findings from the combined breast cancer
sample and the bioinformatic analyses we performed a replication
in the MARIE Study. The minor allele of rs148972953 was not
found to show differential association by oestrogen receptor or
progesterone receptor status (ER: OR=1.18 (0.69–2.02); PR:
OR=0.97 (0.60–1.58); Table 3). In addition, cases and controls of
the MARIE Study did not differ in the genotype frequency of
rs148972953 (Chi-Square Test; p = 0.60).
Based on the results of the bioinformatics analysis, we
hypothesized that rs148972953 could be associated with tumour
metastasis. However, our assumption was not supported in the
MARIE Study. Compared to patients carrying the wildtype of
rs148972953 polymorphism, carriers of the minor allele of
rs148972953 were neither more likely to have metastasis at
baseline (OR=1.76 (0.62–4.96)) nor were they at higher risk of
distant disease-free survival (HR=0.96 (0.75–1.23)) (Table 4). The
genetic status at rs148972953 did not modify the response to
primary hormone therapy (overall survival: HR=0.83 (0.35–2.07);
distant disease free survival: HR=0.96 (0.72–1.29); recurrence-
free survival: HR=1.01 (0.76–1.35)). Carrying the minor allele of
rs148972953 was also not associated with the time until tumour
relapse (Mann-Whitney test; p = 0.947).
Discussion
Bioinformatic analysis of high-throughput cancer microarrays
available on the public domain Oncomine [46,47] revealed that
LAMTOR2 (p14) is significantly up-regulated in breast cancer cells.
Interestingly, two independent publications also reported an up-
regulation of p14 in invasive ductal breast carcinomas [46,48]. In
addition, LAMTOR3 (Mp1) was also found to be up-regulated in
invasive ductal breast carcinomas [49]. Invasive ductal breast
carcinoma is the most common type of breast cancer, comprising
70% to 80% of all cases. It commonly spreads to the regional
lymph nodes and carries a poor prognosis. Interestingly,
LAMTOR3 (Mp1) was also reported to exhibit reduced levels in
the stroma of invasive breast carcinoma [50]. The apparently
opposing observations may indicate that Mp1 is differentially
regulated in stroma and tumour cells. In addition, a recent
publication reported that LAMTOR3 (Mp1) was required for the
survival of oestrogen receptor positive breast cancer cell lines [26].
Taking into consideration the above data, we hypothesized that
LAMTOR components may indeed play a relevant role in breast
cancer progression and are not simply innocent bystanders.
Changes in intracellular protein levels can depend on variation
in the rates of transcription, translation and degradation. In this
project, we searched for mutations in the genomic regions of
LAMTOR2 and LAMTOR3 that could contribute to the aetiology
of breast cancer by altering any of the above mentioned processes.
We initially hypothesized that somatic, cancer-tissue-specific
mutations in LAMTOR2 and LAMTOR3 could be associated with
breast cancer progression and metastasis. We additionally
expected that several rare instead of common variants would be
detected and those rare variants were not expected to be already
listed in databases. Therefore, we applied a discovery stage by
sequencing the exons of LAMTOR2 and LAMTOR3 in 50
cancerous tissues and the corresponding peripheral leukocyte
DNA and observed no differences in the identified mutations
between the two tissues. The identified mutations were investigat-
ed in two different case samples (Risk Prediction of Breast Cancer
Metastasis Study and MARIE cases) as well as two different
control samples (SAPHIR women and MARIE controls).
Despite the promising results in the initial study, the replication
study failed to support an association between the SNP
rs148972953 in LAMTOR3 and both oestrogen and progesterone
receptor status and metastasis. The present work does not exclude
that the observed polymorphisms may play a role in other disease
contexts or that other not yet identified polymorphisms in
LAMTOR2 and LAMTOR3 may in fact contribute to breast
cancer aetiology. We would also like to emphasize that genetic
variation is not the only factor contributing to disease progression.
Many regulatory aspects, in particular those controlling protein
stability, posttranslational modifications and association with
binding partners, play a fundamental role in determining how
much and how active a protein actually is. As discussed before,
previous publications identified the LAMTOR complex as a
convergence point of key signalling pathways: MAPK and mTOR.
Due to the well established role of both signalling cascades in
breast cancer progression, and the recent implication of LAM-
TOR3 in oestrogen receptor positive breast cancer, we leave open
the possibility of therapeutically targeting the complex as
previously proposed by others [26].
Although the LAMTOR complex was independently demon-
strated to be involved in breast cancer [46,48,49,50], neither
LAMTOR2 nor LAMTOR3 came up as hits in genome-wide
association studies (GWAS) with any kind of disease or trait as
indexed by the catalogue of published GWAS [51]. One reason for
this could be that some gene regions are poorly covered by recent
SNP arrays; e.g. rs148972953 is currently neither available on any
commercial genotyping array nor can it be imputed based on
HapMap data. However, the region 4q23, in which LAMTOR3 is
located, showed signals of associations with upper aerodigestive
tract cancers [52] and oesophageal cancer [53] indicating that the
region per se is interesting for cancer. Therefore, future studies
including a dense map of SNPs from the LAMTOR complex
including the regulatory regions might reveal implications of
Table 4. Genetic association of rs148972953 with risk of
having metastasis in MARIE breast cancer cases.
Wild-type
(GG)
Carrier
(AG or AA)
Metastasis at Yes 73 4
baseline No 2221 69
p-value 0.276
OR (95% CI) 1 1.76 (0.62–4.96)
Metastasis after Yes 203 8
primary treatment No 2252 66
p-value 0.435
OR (95% CI) 1 1.34 (0.63–2.84)
Notes:
The analysis was only performed in breast cancer cases of the MARIE Study. At
baseline, 2367 patients suffered from a primary invasive breast cancer and 159
patients suffered from in situ breast cancer; those 159 patients were excluded
for this analysis. In the Risk Prediction of Breast Cancer Metastasis Study,
information on metastasis was either missing in most patients or the follow-up
time was too short for the development of metastasis after primary treatment.
OR … odds ratio.
95% CI … 95% confidence interval.
doi:10.1371/journal.pone.0053768.t004
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genetic associations of LAMTOR2 and LAMTOR3 with breast
cancer.
The present study constitutes a good example for the necessity
and importance of replication in genetic association studies. Small
cohorts intrinsically increase the number of false positives that are
accepted. Replication in larger populations is therefore funda-
mental to separate the wheat from the chaff.
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